Efficacy of an Educational and Counseling Intervention on Adherence to Highly Active Antiretroviral Therapy: French Prospective Controlled Study

REFERENCES

• Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999;13:S271–278.
   PubMed Web of Science ®Google Scholar
• Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–1983.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Perry S, Charlebois ED, et al. Non-adher-ence to highly active antiretroviral therapy predicts pro-gression to AIDS. AIDS. 200115: 1181–1183.
   Google Scholar
• Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS. 1999;13:1771–1778.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Panel on Clini-cal Practices for Treatment of HIV Infections. Guidelines for the Use of Antiretro viral Agents in HIV Infected Adults and Adolescents. Washington, DC: The Henry J. Kaiser Family Foundation; 2001.
   Google Scholar
• Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective random-ized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:221–228.
   PubMed Web of Science ®Google Scholar
• Knobel H, Carmona A, Lopez JL, et al. Adherence to very active antiretroviral treatment: impact of individualized as-sessment. Enferm lnfecc Microbiol Clin. 1999;17:78–81.
   PubMedGoogle Scholar
• Haddad M, Inch C, Glazier RH, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS (Cochrane review). Cochrane Database Syst Rev. 2000;3.
   Google Scholar
• Haynes RB, McDonald H, Garg AX, Montague P. Interven-tions for helping patients to follow prescriptions for medi-cations. Cochrane Database Syst Rev. 2002:CD000011.
   PubMedGoogle Scholar
• Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31\(suppl 3):S154–5157.
   PubMed Web of Science ®Google Scholar
• Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav. 1996;21:835–842.
   PubMed Web of Science ®Google Scholar
• Naguy V, Wolfe G. Cognitive predictors of compliance in chronic disease patients. Med Care. 1984;22:912–921.
   PubMed Web of Science ®Google Scholar
• Brandimonte MA, Passolunghi MC. The effect of cue-famil-iarity, cue-distinctiveness, and retention interval on pro-spective remembering. Q J Exp Psychol A. 1994;47:565–587.
   PubMedGoogle Scholar
• Chesney MA, Morin M, Sherr L. Adherence to HIV combi-nation therapy. Soc Sci Med. 2000;50:1599–1605.
   PubMed Web of Science ®Google Scholar
• Swindells S, Mohr J, Justis JC, et al. Quality of life in patients with human immunodeficiency virus infection: im-pact of social support, coping style and hopelessness. Int J STD AIDS. 1999;10:383–391.
   PubMed Web of Science ®Google Scholar
• Singh N, Squier C, Sivek C, Wagener M, Nguyen M, Yu V. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–269.
   PubMed Web of Science ®Google Scholar
• Crespo-Fierro M. Compliance/adherence and care man-agement in HIV disease. AIDS Care. 1997;8:43–54.
   Google Scholar
• Marlatt G, Gordon J. Determinants of relapse: implications for the maintenance of behavior change. In: Davidson P, Davidson S. eds. Behavioral Medicine: Changing Health Lifestyles. New York: Brunner/Mazel; 1980:410–452.
   Google Scholar
• Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst. 1993;85:1138–1148.
   PubMed Web of Science ®Google Scholar
• Chesney MA, Ickovics JR, Chambers DB, et al. Self-re-ported adherence to antiretroviral medications among par-ticipants in HIV clinical trials: the AACTG adherence instru-ments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255–266.
   PubMed Web of Science ®Google Scholar
• Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 200115: 2441–2444.
   Google Scholar
• Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO Cohort. J Acquir Im-mune Defic Syndr. 2001;28:232–239.
   PubMed Web of Science ®Google Scholar
• Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected pa-tients and their impact on adherence to HAART. HIV Clin Trials. 2001;2: 38–45.
   PubMedGoogle Scholar
• Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale [in French]. Psychiatrie et Psychobiologie. 1989;4:163–166.
   Google Scholar
• Haynes R, McKibbon K, Kanani R. Systematic review of randomized trials of interventions to assist patients to fol-low prescriptions for medications. Lancet. 1996;100:258–268.
   Google Scholar
• Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;17:43–49.
   Google Scholar
• Myers L, Midence K. Adherence to Treatment in Medical Conditions. The Netherlands: Harwood Academic; 1998.
   Google Scholar
• Sikkema K, Kelly J. Behavioral medicine interventions can improve the quality of life and health of persons with HIV disease. J Behav Med. 1996;18:40–48.
   Web of Science ®Google Scholar
• Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35–43.
   PubMed Web of Science ®Google Scholar
• Ajzen I, Fishbein M. Understanding Attitudes and Predict-ing Social Behavior. Englewood Cliffs, NJ: Prentice Hall; 1980.
   Google Scholar
• Dunbar-Jacobs J, Dwyer K, Dunning E. Compliance with antihypertensive regimen: a review of the research in the 1980s. Ann Behav Med. 1991;13:31–39.
   Google Scholar
• Broadhead RS, Heckathorn DD, Weakliem DL, et al. Har-nessing peer networks as an instrument for AIDS preven-tion: results from a peer-driven intervention. Public Health Rep. 1998;113\(suppl 1):42–57.
   PubMed Web of Science ®Google Scholar
• Munzenberger N, Cassuto J, Gastaut J, Souville M, Morin M, Moatti J. Observance during clinical trials in HIV infec-tion. A discontinuity between patient history and trial logic. Presse Med. 1997;26:358–365.
   PubMed Web of Science ®Google Scholar
• Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481–1496.
   PubMed Web of Science ®Google Scholar
• Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Read. 2000;10:177–185.
   PubMedGoogle Scholar
• Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123–128.
   PubMed Web of Science ®Google Scholar
• Duran S, Soles C, Spire B, et al. "Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?" A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS. 2001;15:1075–1077.
   PubMed Web of Science ®Google Scholar
• Duong M, Piroth L, Peytavin G, et al. Value of patient self-report and plasma human immunodeficiency virus pro-tease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis. 2001;33:386–392.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in pre-dicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy pre-dicts biologic outcomes for human immunodeficiency vi-rus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.
   PubMed Web of Science ®Google Scholar